Aligos Therapeutics, Inc.
ALGS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001799448
Insider trades, last 90 days
None
- No open-market purchases or sales were filed in the last 90 days.
13F holders, Q2 2026
31
- −4 vs. Q1 2026
- Total value $13.23M
Superinvestors holding ALGS
1
- At the end of Q2 2026
Price chart
Latest insider trades
View all: Latest insider tradesOpen-market purchases and sales by ALGS insiders, newest first.
| Filed (ET) | Trade date | Insider | Transaction | Shares | Avg price | Value | Shares after | Holding change | Filing |
|---|---|---|---|---|---|---|---|---|---|
| Oct 27, 20234:15 PM ET | Oct 25, 2023 | Nuechterlein CaroleDirector, 10% Owner | PPurchaseCommon Stock | +7.93M | $0.7568 | +$6M | 11.03M | +256.6% | SEC |
| Oct 27, 20234:15 PM ET | Oct 25, 2023 | Nuechterlein CaroleDirector, 10% Owner | PPurchaseCommon Stock · Derivative | +3.97M | $0.125 | +$495.85K | 3.97M | – | SEC |
Top 5 13F holders, Q2 2026
View all: Top 5 13F holders, Q2 2026The largest institutional positions in ALGS at the end of Q2 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Deep Track Capital, LP | 444,110 | $2.56M | 0.04% | 00.0% | Unchanged |
| Alyeska Investment Group, L.P. | 412,000 | $2.38M | 0.01% | 00.0% | Unchanged |
| Sio Capital Management, LLC | 327,237 | $1.89M | 0.32% | 00.0% | Unchanged |
| MARSHALL WACE, LLP | 246,579 | $1.42M | 0.00% | −20,556−7.7% | Reduced |
| Woodline Partners LP | 177,362 | $1.02M | 0.00% | 00.0% | Unchanged |